Bausch Health Companies (NYSE:BHC) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Bausch Health Companies (NYSE:BHC) from a hold rating to a buy rating in a report published on Saturday morning.

Other equities research analysts also recently issued research reports about the company. Scotiabank lowered their price objective on Bausch Health Companies from $10.00 to $8.50 and set a sector perform rating for the company in a research report on Friday, August 2nd. Raymond James began coverage on Bausch Health Companies in a research report on Wednesday, July 10th. They issued a market perform rating and a $8.00 price objective for the company. Jefferies Financial Group lowered their price objective on Bausch Health Companies from $13.00 to $9.00 and set a buy rating for the company in a research report on Wednesday, August 7th. Piper Sandler downgraded Bausch Health Companies from a neutral rating to an underweight rating and lowered their price target for the company from $9.00 to $3.00 in a research report on Friday, August 2nd. Finally, Royal Bank of Canada lowered their price target on Bausch Health Companies from $10.00 to $8.50 and set a sector perform rating for the company in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $7.33.

Bausch Health Companies Stock Down 0.3 %

NYSE BHC opened at $6.19 on Friday. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -4.99 and a beta of 0.75. The business has a fifty day moving average of $6.31 and a 200-day moving average of $7.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.33 billion. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. During the same quarter in the previous year, the business earned $0.81 earnings per share. As a group, analysts anticipate that Bausch Health Companies will post 3.61 EPS for the current year.

Insider Buying and Selling at Bausch Health Companies

In other news, EVP Seana Carson sold 13,370 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the sale, the executive vice president now owns 435,198 shares of the company’s stock, valued at $2,702,579.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bausch Health Companies

Several institutional investors and hedge funds have recently modified their holdings of BHC. Principal Securities Inc. purchased a new stake in shares of Bausch Health Companies in the fourth quarter worth about $31,000. Salem Investment Counselors Inc. purchased a new stake in shares of Bausch Health Companies in the first quarter worth about $32,000. Headlands Technologies LLC purchased a new stake in shares of Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies in the second quarter worth about $71,000. Finally, Certuity LLC acquired a new position in shares of Bausch Health Companies in the second quarter worth about $75,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.